Cidara Therapeutics Enters Merger Agreement with Merck

Cidara Therapeutics ( (CDTX) ) has provided an update.

On November 13, 2025, Cidara Therapeutics entered into a merger agreement with Merck, where Merck will acquire Cidara for $221.50 per share, totaling approximately $9.2 billion. This acquisition aims to diversify Merck’s portfolio by including Cidara’s investigational antiviral agent, CD388, which is currently in Phase 3 trials for preventing influenza in high-risk individuals. The merger is expected to close in the first quarter of 2026, pending regulatory approvals and other customary conditions. This strategic move aligns with Merck’s science-led business development strategy and is anticipated to enhance its pipeline, potentially driving growth and providing significant value to shareholders.

The most recent analyst rating on (CDTX) stock is a Hold with a $102.00 price target. To see the full list of analyst forecasts on Cidara Therapeutics stock, see the CDTX Stock Forecast page.

Spark’s Take on CDTX Stock

According to Spark, TipRanks’ AI Analyst, CDTX is a Neutral.

Cidara Therapeutics’ overall stock score is primarily influenced by its challenging financial performance, with significant losses and reliance on external financing. However, the positive technical indicators and promising developments in CD388’s Phase III trials, supported by strong funding and regulatory advancements, provide a balanced outlook.

To see Spark’s full report on CDTX stock, click here.

More about Cidara Therapeutics

Cidara Therapeutics is a biotechnology company based in San Diego, California, specializing in the development of drug-Fc conjugate therapeutics. Their lead candidate, CD388, is a long-acting antiviral designed to prevent influenza in high-risk individuals, leveraging their proprietary Cloudbreak platform.

Average Trading Volume: 868,399

Technical Sentiment Signal: Buy

Current Market Cap: $3.37B

For an in-depth examination of CDTX stock, go to TipRanks’ Overview page.